UA117801C2 - Лікування неврологічного порушення за допомогою антитіла, яке має низьку афінність до рецептора гематоенцефалічного бар'єру - Google Patents
Лікування неврологічного порушення за допомогою антитіла, яке має низьку афінність до рецептора гематоенцефалічного бар'єруInfo
- Publication number
- UA117801C2 UA117801C2 UAA201308125A UAA201308125A UA117801C2 UA 117801 C2 UA117801 C2 UA 117801C2 UA A201308125 A UAA201308125 A UA A201308125A UA A201308125 A UAA201308125 A UA A201308125A UA 117801 C2 UA117801 C2 UA 117801C2
- Authority
- UA
- Ukraine
- Prior art keywords
- brain barrier
- blood brain
- low affinity
- receptor antibodies
- uses therefor
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
- A61K47/6849—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a receptor, a cell surface antigen or a cell surface determinant
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K49/00—Preparations for testing in vivo
- A61K49/001—Preparation for luminescence or biological staining
- A61K49/0013—Luminescence
- A61K49/0017—Fluorescence in vivo
- A61K49/005—Fluorescence in vivo characterised by the carrier molecule carrying the fluorescent agent
- A61K49/0058—Antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
- A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
- A61K51/1093—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody conjugates with carriers being antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2881—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against CD71
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/40—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against enzymes
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/46—Hybrid immunoglobulins
- C07K16/468—Immunoglobulins having two or more different antigen binding sites, e.g. multifunctional antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/54—F(ab')2
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Abstract
Винахід стосується лікування неврологічного порушення, вибраного з групи, що складається з хвороби Альцгеймера (AD), удару, деменції, м'язової дистрофії (MD), розсіяного склерозу (MS), аміотрофічного бічного склерозу (ALS), муковісцидозу, синдрому Ангельмана, синдрому Ліддла, хвороби Паркінсона, хвороби Піка, хвороби Педжета, раку і травматичного ушкодження головного мозку у ссавця, за допомогою антитіла, яке зв'язується з рецептором трансферину (TfR), де антитіло вибране так, що має IC50 від 100 нМ до 100 мкМ відносно TfR і таким чином збільшує доставку в ЦНС антитіла та зв'язаного з ним лікарського препарату або візуалізуючої сполуки через гематоенцефалічний бар'єр.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US41822310P | 2010-11-30 | 2010-11-30 | |
PCT/US2011/062445 WO2012075037A1 (en) | 2010-11-30 | 2011-11-29 | Low affinity blood brain barrier receptor antibodies and uses therefor |
Publications (1)
Publication Number | Publication Date |
---|---|
UA117801C2 true UA117801C2 (uk) | 2018-10-10 |
Family
ID=45316102
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
UAA201308125A UA117801C2 (uk) | 2010-11-30 | 2011-11-29 | Лікування неврологічного порушення за допомогою антитіла, яке має низьку афінність до рецептора гематоенцефалічного бар'єру |
Country Status (34)
Country | Link |
---|---|
US (5) | US20120171120A1 (uk) |
EP (2) | EP2646470B1 (uk) |
JP (3) | JP6125430B2 (uk) |
KR (3) | KR102099462B1 (uk) |
CN (2) | CN103443125B (uk) |
AR (1) | AR084020A1 (uk) |
AU (2) | AU2011336716B2 (uk) |
BR (1) | BR112013013083A2 (uk) |
CA (1) | CA2818173C (uk) |
CL (1) | CL2013001535A1 (uk) |
CO (1) | CO6721052A2 (uk) |
CR (1) | CR20130255A (uk) |
CY (1) | CY1118906T1 (uk) |
DK (1) | DK2646470T3 (uk) |
EA (1) | EA034333B1 (uk) |
EC (1) | ECSP13012724A (uk) |
ES (1) | ES2631356T3 (uk) |
HR (1) | HRP20170590T1 (uk) |
IL (1) | IL282877A (uk) |
LT (1) | LT2646470T (uk) |
MA (1) | MA34749B1 (uk) |
MX (1) | MX358367B (uk) |
MY (1) | MY188469A (uk) |
NZ (2) | NZ706751A (uk) |
PE (1) | PE20140981A1 (uk) |
PL (1) | PL2646470T3 (uk) |
PT (1) | PT2646470T (uk) |
RS (1) | RS55920B1 (uk) |
SG (1) | SG190900A1 (uk) |
SI (1) | SI2646470T1 (uk) |
TW (3) | TW201305200A (uk) |
UA (1) | UA117801C2 (uk) |
WO (1) | WO2012075037A1 (uk) |
ZA (1) | ZA201303572B (uk) |
Families Citing this family (110)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP5959795B2 (ja) | 2006-08-18 | 2016-08-02 | アーメイゲン・テクノロジーズ・インコーポレイテッドArmagen Technologies, Inc. | 血液脳関門送達のための物質 |
CA2694762A1 (en) | 2007-07-27 | 2009-02-05 | Armagen Technologies, Inc. | Methods and compositions for increasing alpha-l-iduronidase activity in the cns |
US20090162359A1 (en) | 2007-12-21 | 2009-06-25 | Christian Klein | Bivalent, bispecific antibodies |
US9676845B2 (en) | 2009-06-16 | 2017-06-13 | Hoffmann-La Roche, Inc. | Bispecific antigen binding proteins |
HUE044865T2 (hu) | 2009-10-09 | 2019-11-28 | Armagen Inc | Eljárások és készítmények a központi idegrendszerben iduronát-2-szulfatáz-aktivitás növelésére |
EP3252072A3 (en) | 2010-08-03 | 2018-03-14 | AbbVie Inc. | Dual variable domain immunoglobulins and uses thereof |
EP2638070B1 (en) | 2010-11-10 | 2016-10-19 | F.Hoffmann-La Roche Ag | Methods and compositions for neural disease immunotherapy |
CN103443125B (zh) | 2010-11-30 | 2019-05-03 | 霍夫曼-拉罗奇有限公司 | 低亲和力血脑屏障受体抗体及其用途 |
BR112013019975A2 (pt) | 2011-02-28 | 2017-08-01 | Hoffmann La Roche | proteínas de ligação de antígeno, composição farmacêutica, uso de uma proteína de ligação de antígeno, método para o tratamento de um paciente e método para a preparação de uma proteína de ligação de antígeno, ácido nucleico, vetor e célula hospedeira" |
EP2681240B1 (en) | 2011-02-28 | 2017-08-16 | F. Hoffmann-La Roche AG | Monovalent antigen binding proteins |
EP2852618A2 (en) * | 2012-05-21 | 2015-04-01 | F. Hoffmann-La Roche AG | Methods for improving safety of blood-brain barrier transport |
CN107973856B (zh) | 2012-07-04 | 2021-11-23 | 弗·哈夫曼-拉罗切有限公司 | 共价连接的抗原-抗体缀合物 |
EP3315514A1 (en) * | 2012-08-29 | 2018-05-02 | F. Hoffmann-La Roche AG | Blood brain barrier shuttle |
EP2928919A2 (en) * | 2012-12-04 | 2015-10-14 | AbbVie Inc. | Blood-brain barrier (bbb) penetrating dual specific binding proteins |
US9636418B2 (en) | 2013-03-12 | 2017-05-02 | Amgen Inc. | Potent and selective inhibitors of NAV1.7 |
UY35397A (es) | 2013-03-12 | 2014-10-31 | Amgen Inc | INHIBIDORES POTENTES Y SELECTIVOS DE NaV1.7 |
US9580486B2 (en) | 2013-03-14 | 2017-02-28 | Amgen Inc. | Interleukin-2 muteins for the expansion of T-regulatory cells |
EP2999716A2 (en) | 2013-05-20 | 2016-03-30 | F. Hoffmann-La Roche AG | Anti-transferrin receptor antibodies and methods of use |
EP3730516A1 (en) * | 2013-07-22 | 2020-10-28 | Armagen, Inc. | Methods and compositions for increasing enzyme activity in the cns |
WO2015014884A1 (en) * | 2013-08-02 | 2015-02-05 | F. Hoffmann-La Roche Ag | Therapeutic fusion protein |
EP3044323B1 (en) | 2013-09-13 | 2022-04-06 | F. Hoffmann-La Roche AG | Methods for detecting and quantifying host cell protein in cell lines |
MX2016003202A (es) * | 2013-09-13 | 2016-06-07 | Genentech Inc | Metodos y composiciones que comprenden polipeptidos recombinantes purificados. |
WO2015052230A1 (en) | 2013-10-11 | 2015-04-16 | F. Hoffmann-La Roche Ag | Multispecific domain exchanged common variable light chain antibodies |
EP3071597B1 (en) * | 2013-11-21 | 2020-07-29 | F.Hoffmann-La Roche Ag | Anti-alpha-synuclein antibodies and methods of use |
US9579374B2 (en) | 2013-12-04 | 2017-02-28 | The Johns Hopkins University | Method for rapidly designing pharmaceutical preparations for preventing viral infection |
PL3083680T3 (pl) | 2013-12-20 | 2020-06-29 | F. Hoffmann-La Roche Ag | Humanizowane przeciwciała przeciwko białku tau(pS422) i sposoby stosowania |
CA2929149A1 (en) | 2013-12-20 | 2015-06-25 | F. Hoffmann-La Roche Ag | Improved recombinant polypeptide production methods |
EP3088518A4 (en) | 2013-12-25 | 2017-09-20 | JCR Pharmaceuticals Co., Ltd. | Novel anti-transferrin receptor antibody that passes through blood-brain barrier |
WO2015101586A1 (en) * | 2014-01-03 | 2015-07-09 | F. Hoffmann-La Roche Ag | Bispecific anti-hapten/anti-blood brain barrier receptor antibodies, complexes thereof and their use as blood brain barrier shuttles |
CN105873615B (zh) | 2014-01-03 | 2020-12-25 | 豪夫迈·罗氏有限公司 | 共价连接的helicar-抗helicar抗体缀合物及其用途 |
CN105873616B (zh) | 2014-01-03 | 2020-06-05 | 豪夫迈·罗氏有限公司 | 共价连接的多肽毒素-抗体缀合物 |
PL3092251T3 (pl) * | 2014-01-06 | 2021-08-02 | F. Hoffmann-La Roche Ag | Jednowartościowe moduły transportera wahadłowego przez barierę krew-mózg |
MX2016011561A (es) * | 2014-03-06 | 2017-04-13 | Nat Res Council Canada | Anticuerpos especificos para el receptor del factor de crecimiento similar a insulina 1 y usos de los mismos. |
AU2014385799B2 (en) | 2014-03-06 | 2020-10-22 | National Research Council Of Canada | Insulin-like growth factor 1 receptor -specific antibodies and uses thereof |
AU2014385801B2 (en) | 2014-03-06 | 2020-11-12 | National Research Council Of Canada | Insulin-like growth factor 1 receptor -specific antibodies and uses thereof |
EP3129051A1 (en) | 2014-04-08 | 2017-02-15 | Prothena Biosciences Limited | Blood-brain barrier shuttles containing antibodies recognizing alpha-synuclein |
WO2015175375A1 (en) | 2014-05-13 | 2015-11-19 | Short Jay M | Conditionally active biological proteins |
CA2951391C (en) | 2014-06-10 | 2021-11-02 | Amgen Inc. | Apelin polypeptides |
AR100978A1 (es) | 2014-06-26 | 2016-11-16 | Hoffmann La Roche | LANZADERAS CEREBRALES DE ANTICUERPO HUMANIZADO ANTI-Tau(pS422) Y USOS DE LAS MISMAS |
US11111288B2 (en) | 2014-08-28 | 2021-09-07 | Bioatla, Inc. | Conditionally active chimeric antigen receptors for modified t-cells |
JP7286267B2 (ja) | 2014-08-28 | 2023-06-05 | バイオアトラ インコーポレイテッド | 修飾t細胞に対する条件的活性型キメラ抗原受容体 |
EP3218411B1 (en) | 2014-11-14 | 2022-01-12 | Ossianix, Inc. | Variable new antigen receptors (vnars) directed against transferrin receptor (tfr) and their use |
CN107108745B (zh) | 2014-11-19 | 2021-01-12 | 基因泰克公司 | 抗bace1的抗体和其用于神经疾病免疫疗法的用途 |
US10508151B2 (en) | 2014-11-19 | 2019-12-17 | Genentech, Inc. | Anti-transferrin receptor antibodies and methods of use |
US11008403B2 (en) | 2014-11-19 | 2021-05-18 | Genentech, Inc. | Anti-transferrin receptor / anti-BACE1 multispecific antibodies and methods of use |
PL3227332T3 (pl) | 2014-12-03 | 2020-06-15 | F. Hoffmann-La Roche Ag | Wielospecyficzne przeciwciała |
WO2016094566A2 (en) * | 2014-12-10 | 2016-06-16 | Genentech, Inc. | Blood brain barrier receptor antibodies and methods of use |
US10093733B2 (en) | 2014-12-11 | 2018-10-09 | Abbvie Inc. | LRP-8 binding dual variable domain immunoglobulin proteins |
CR20170510A (es) | 2015-04-10 | 2018-02-26 | Amgen Inc | Muteínas de interuquina 2 para la expansión de células t regulatorias |
CA3176004A1 (en) | 2015-05-04 | 2016-11-10 | Cytomx Therapeutics, Inc. | Anti-cd71 antibodies, activatable anti-cd71 antibodies, and methods of use thereof |
CN107847588B (zh) | 2015-05-20 | 2021-12-28 | 免疫功坊股份有限公司 | 具有靶向部分及效应部分的分子构建体及其应用 |
TW201710286A (zh) | 2015-06-15 | 2017-03-16 | 艾伯維有限公司 | 抗vegf、pdgf及/或其受體之結合蛋白 |
CN107849555B (zh) | 2015-06-24 | 2022-01-04 | Jcr制药股份有限公司 | 通过血脑屏障的抗人转铁蛋白受体抗体 |
LT3313879T (lt) | 2015-06-24 | 2022-03-25 | F. Hoffmann-La Roche Ag | Antikūnai prieš transferino receptorių su pritaikytu giminingumu |
CA2990565A1 (en) | 2015-06-24 | 2016-12-29 | Jcr Pharmaceuticals Co., Ltd. | Fusion protein containing bdnf and anti-human transferrin receptor antibody |
US9862763B2 (en) | 2015-06-24 | 2018-01-09 | Hoffmann-La Roche Inc. | Humanized anti-tau(pS422) antibodies and methods of use |
AR106189A1 (es) | 2015-10-02 | 2017-12-20 | Hoffmann La Roche | ANTICUERPOS BIESPECÍFICOS CONTRA EL A-b HUMANO Y EL RECEPTOR DE TRANSFERRINA HUMANO Y MÉTODOS DE USO |
NZ741067A (en) * | 2015-10-02 | 2023-07-28 | Hoffmann La Roche | Bispecific anti-human cd20/human transferrin receptor antibodies and methods of use |
JP2019514994A (ja) * | 2016-05-09 | 2019-06-06 | アネクソン,インコーポレーテッド | 脊髄性筋萎縮症を治療するための組成物及び方法 |
ES2930255T3 (es) | 2016-05-13 | 2022-12-09 | Bioatla Inc | Anticuerpos anti-Ror2, fragmentos de anticuerpos, sus inmunoconjugados y usos de los mismos |
AU2017297804A1 (en) | 2016-07-14 | 2019-01-24 | Bioarctic Ab | Brain delivery protein |
AU2017311040B2 (en) | 2016-08-06 | 2023-08-31 | Ossianix, Inc. | In vivo methods for selecting peptides that cross the blood brain barrier, related compositions and methods of use |
CN106442967B (zh) * | 2016-09-27 | 2018-05-15 | 鸿运华宁(杭州)生物医药有限公司 | 一种检测跨膜蛋白单克隆抗体亲和力的方法 |
US10702589B2 (en) | 2016-10-04 | 2020-07-07 | Ann And Robert H. Lurie Children's Hospital Of Chicago | Compositions and methods of treating neurological disorder and stress-induced conditions |
CN109983031B (zh) | 2016-12-26 | 2022-11-25 | Jcr制药股份有限公司 | 通过血脑屏障的新的抗人转铁蛋白受体抗体 |
EP3561058A4 (en) | 2016-12-26 | 2020-07-22 | JCR Pharmaceuticals Co., Ltd. | FUSION PROTEIN INCLUDING BDNF |
JP2020508049A (ja) | 2017-02-17 | 2020-03-19 | デナリ セラピューティクス インコーポレイテッドDenali Therapeutics Inc. | 操作されたトランスフェリン受容体結合ポリペプチド |
US10143187B2 (en) | 2017-02-17 | 2018-12-04 | Denali Therapeutics Inc. | Transferrin receptor transgenic models |
US10457717B2 (en) | 2017-02-17 | 2019-10-29 | Denali Therapeutics Inc. | Engineered polypeptides |
US10363245B2 (en) | 2017-02-22 | 2019-07-30 | The Board Of Regents Of The University Of Texas System | Methods for treating CNS lesions |
WO2019023809A1 (en) | 2017-08-02 | 2019-02-07 | Stressmarq Biosciences Inc. | ANTIBODIES BINDING TO ACTIVE ALPHA-SYNUCLEINE |
ES2817910T3 (es) * | 2017-08-04 | 2021-04-08 | Alzheimur 2012 S L | Uso de un anticuerpo antipresenilina para la prevención y/o tratamiento del cáncer |
CA3072051A1 (en) * | 2017-08-10 | 2019-02-14 | Denali Therapeutics Inc. | Affinity-based methods for using transferrin receptor-binding proteins |
EP3904389A1 (en) | 2017-10-02 | 2021-11-03 | Denali Therapeutics Inc. | Fusion proteins comprising enzyme replacement therapy enzymes |
US11780932B2 (en) | 2017-10-09 | 2023-10-10 | Wisconsin Alumni Research Foundation | Antibodies targeting glioblastoma stem-like cells and methods of use thereof |
EP3704149A1 (en) | 2017-11-02 | 2020-09-09 | Ossianix, Inc. | Improved tfr-selective binding peptides capable of crossing the blood brain barrier |
US10688191B2 (en) | 2018-01-19 | 2020-06-23 | Hr Biomed, Llc | Delivery of a chemotherapy agent across the blood-brain barrier |
RU2020129184A (ru) | 2018-02-07 | 2022-03-09 | Регенерон Фармасьютикалз, Инк. | Способы и композиции для доставки терапевтического белка |
WO2019243502A1 (en) | 2018-06-21 | 2019-12-26 | Novo Nordisk A/S | Novel compounds for treatment of obesity |
US11911484B2 (en) | 2018-08-02 | 2024-02-27 | Dyne Therapeutics, Inc. | Muscle targeting complexes and uses thereof for treating myotonic dystrophy |
JP2021532831A (ja) | 2018-08-02 | 2021-12-02 | ダイン セラピューティクス, インコーポレーテッドDyne Therapeutics, Inc. | ジストロフィン異常症を処置するための筋標的化複合体およびそれらの使用 |
US20210395381A1 (en) | 2018-09-14 | 2021-12-23 | Ossianix, Inc. | Tfr-specific binding moieties and transcytosis method to select vnars that cross cellular barriers |
KR20200047937A (ko) * | 2018-10-26 | 2020-05-08 | 재단법인 목암생명과학연구소 | Ids를 포함하는 융합 단백질 및 이의 용도 |
TW202039581A (zh) * | 2018-12-28 | 2020-11-01 | 日商協和麒麟股份有限公司 | 與TfR結合之雙專一性抗體 |
CN113474369A (zh) | 2019-01-09 | 2021-10-01 | 维克塔-霍洛斯公司 | 转铁蛋白受体结合分子、其偶联物和它们的用途 |
CN116063520A (zh) | 2019-01-30 | 2023-05-05 | 真和制药有限公司 | 抗gal3抗体及其用途 |
EP4013876A1 (en) | 2019-08-14 | 2022-06-22 | Codiak BioSciences, Inc. | Extracellular vesicle-nlrp3 antagonist |
EP4013875A1 (en) | 2019-08-14 | 2022-06-22 | Codiak BioSciences, Inc. | Extracellular vesicles with stat3-antisense oligonucleotides |
JP2022544288A (ja) | 2019-08-14 | 2022-10-17 | コディアック バイオサイエンシーズ, インコーポレイテッド | CEBP/βを標的とする細胞外小胞-ASO構築物 |
JP2022544290A (ja) | 2019-08-14 | 2022-10-17 | コディアック バイオサイエンシーズ, インコーポレイテッド | Krasを標的とするアンチセンスオリゴヌクレオチドを有する細胞外小胞 |
EP4013877A1 (en) | 2019-08-14 | 2022-06-22 | Codiak BioSciences, Inc. | Extracellular vesicle-aso constructs targeting stat6 |
WO2021048034A1 (en) | 2019-09-09 | 2021-03-18 | F. Hoffmann-La Roche Ag | Glucocerebrosidase mutants |
US20230241089A1 (en) | 2019-09-25 | 2023-08-03 | Codiak Biosciences, Inc. | Sting agonist comprising exosomes for treating neuroimmunological disorders |
TWI739220B (zh) * | 2019-11-26 | 2021-09-11 | 亞瑟瑞智科技管理顧問股份有限公司 | 包含克拉維酸與丙戊酸之組合物及其用途 |
CN114981297A (zh) | 2019-12-23 | 2022-08-30 | 戴纳立制药公司 | 颗粒蛋白前体变体 |
US20230111147A1 (en) * | 2020-01-10 | 2023-04-13 | Dyne Therapeutics, Inc. | Muscle targeting complexes and uses thereof for modulation of genes associated with muscle health |
BR112022013892A2 (pt) * | 2020-01-13 | 2022-10-04 | Truebinding Inc | Anticorpos anti-gal3 e métodos de uso |
WO2021184021A1 (en) | 2020-03-13 | 2021-09-16 | Codiak Biosciences, Inc. | Extracellular vesicle-aso constructs targeting pmp22 |
WO2021184020A1 (en) | 2020-03-13 | 2021-09-16 | Codiak Biosciences, Inc. | Methods of treating neuroinflammation |
WO2021184017A1 (en) | 2020-03-13 | 2021-09-16 | Codiak Biosciences, Inc. | Extracellular vesicles for treating neurological disorders |
WO2022178149A2 (en) | 2021-02-17 | 2022-08-25 | Codiak Biosciences, Inc. | Extracellular vesicle-nlrp3 antagonist |
AU2022291255A1 (en) | 2021-06-11 | 2024-01-04 | Bioarctic Ab | Bispecific binding molecule |
US11638761B2 (en) | 2021-07-09 | 2023-05-02 | Dyne Therapeutics, Inc. | Muscle targeting complexes and uses thereof for treating Facioscapulohumeral muscular dystrophy |
AU2022340568A1 (en) | 2021-09-01 | 2024-03-28 | Biogen Ma Inc. | Anti-transferrin receptor antibodies and uses thereof |
WO2023166168A1 (en) | 2022-03-03 | 2023-09-07 | Vib Vzw | Polystyrene sulfonate for use to treat neurodegenerative diseases |
WO2023198661A1 (en) | 2022-04-12 | 2023-10-19 | F. Hoffmann-La Roche Ag | Fusion proteins targeted to the central nervous system |
US11931421B2 (en) | 2022-04-15 | 2024-03-19 | Dyne Therapeutics, Inc. | Muscle targeting complexes and formulations for treating myotonic dystrophy |
WO2024026488A2 (en) | 2022-07-29 | 2024-02-01 | Regeneron Pharmaceuticals, Inc. | Non-human animals comprising a modified transferrin receptor locus |
WO2024026494A1 (en) | 2022-07-29 | 2024-02-01 | Regeneron Pharmaceuticals, Inc. | Viral particles retargeted to transferrin receptor 1 |
WO2024059056A1 (en) * | 2022-09-12 | 2024-03-21 | Emory University | Methods of managing traumatic brain injury |
Family Cites Families (201)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3773919A (en) | 1969-10-23 | 1973-11-20 | Du Pont | Polylactide-drug mixtures |
JPS55113334A (en) | 1979-02-23 | 1980-09-01 | Hitachi Ltd | Manufacture of passivation film |
US4332785A (en) | 1980-04-09 | 1982-06-01 | University Patents, Inc. | Immunoassay for measurement of reticulocytes, and immunoreactive reagents for use therein |
US4447547A (en) | 1980-04-09 | 1984-05-08 | University Patents, Inc. | Immunoassay for measurement of reticulocytes, and immunoreactive reagents for use therein |
US4626507A (en) | 1980-09-25 | 1986-12-02 | The Salk Institute For Biological Studies | Hybridomas producing monoclonal antibodies specific for a human cell surface glycoprotein |
US4434156A (en) | 1981-10-26 | 1984-02-28 | The Salk Institute For Biological Studies | Monoclonal antibodies specific for the human transferrin receptor glycoprotein |
US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
US4545985A (en) | 1984-01-26 | 1985-10-08 | The United States Of America As Represented By The Secretary, Dept. Of Health And Human Services | Pseudomonas exotoxin conjugate immunotoxins |
JPS6210017A (ja) | 1985-07-04 | 1987-01-19 | Mochida Pharmaceut Co Ltd | トランスフエリンレセプタ−の精製方法 |
US4676980A (en) | 1985-09-23 | 1987-06-30 | The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Target specific cross-linked heteroantibodies |
US4956453A (en) | 1985-12-06 | 1990-09-11 | Cetus Corporation | Anti-human ovarian cancer immunotoxins and methods of use thereof |
US4801575A (en) | 1986-07-30 | 1989-01-31 | The Regents Of The University Of California | Chimeric peptides for neuropeptide delivery through the blood-brain barrier |
US4902505A (en) | 1986-07-30 | 1990-02-20 | Alkermes | Chimeric peptides for neuropeptide delivery through the blood-brain barrier |
US5567610A (en) | 1986-09-04 | 1996-10-22 | Bioinvent International Ab | Method of producing human monoclonal antibodies and kit therefor |
US4892827A (en) * | 1986-09-24 | 1990-01-09 | The United States Of America As Represented By The Department Of Health And Human Services | Recombinant pseudomonas exotoxins: construction of an active immunotoxin with low side effects |
HU205266B (en) | 1987-03-11 | 1992-04-28 | Erba Carlo Spa | Process for producing immunglobuline conjugates |
US5792458A (en) | 1987-10-05 | 1998-08-11 | The United States Of America As Represented By The Department Of Health And Human Services | Mutant diphtheria toxin conjugates |
US5208021A (en) | 1987-10-05 | 1993-05-04 | The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Method of preparing diphtheria immunotoxins |
US5352447A (en) | 1987-10-05 | 1994-10-04 | The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Immunotoxins for treatment of intracranial lesions and as adjunct to chemotherapy |
US5728383A (en) | 1987-10-05 | 1998-03-17 | The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Treatment of tumors of the central nervous system with immunotoxins |
US5231000A (en) * | 1987-10-08 | 1993-07-27 | The Mclean Hospital | Antibodies to A4 amyloid peptide |
US5601819A (en) | 1988-08-11 | 1997-02-11 | The General Hospital Corporation | Bispecific antibodies for selective immune regulation and for selective immune cell binding |
GB8823869D0 (en) | 1988-10-12 | 1988-11-16 | Medical Res Council | Production of antibodies |
US5175384A (en) | 1988-12-05 | 1992-12-29 | Genpharm International | Transgenic mice depleted in mature t-cells and methods for making transgenic mice |
US5217713A (en) | 1988-12-27 | 1993-06-08 | Takeda Chemical Industries, Ltd. | Cytotoxic bispecific monoclonal antibody, its production and use |
CA2006408A1 (en) | 1988-12-27 | 1990-06-27 | Susumu Iwasa | Bispecific monoclonal antibody, its production and use |
CA2011099A1 (en) | 1989-04-19 | 1990-10-19 | Stephen C. Wardlaw | Determination of lymphocyte reactivity to specific antigens in blood |
US5141743A (en) | 1989-04-27 | 1992-08-25 | University Technologies International, Inc. | Method for isolating and purifying transferrin and lactoferrin receptor proteins and vaccines containing the same |
US5292869A (en) | 1989-04-27 | 1994-03-08 | The Board Of Governors Of The University | Method for isolating and purifying transferrin and lactoferrin receptor proteins from bacteria and the preparation of vaccines containing the same |
US5527527A (en) | 1989-09-07 | 1996-06-18 | Alkermes, Inc. | Transferrin receptor specific antibody-neuropharmaceutical agent conjugates |
US5977307A (en) | 1989-09-07 | 1999-11-02 | Alkermes, Inc. | Transferrin receptor specific ligand-neuropharmaceutical agent fusion proteins |
US5154924A (en) | 1989-09-07 | 1992-10-13 | Alkermes, Inc. | Transferrin receptor specific antibody-neuropharmaceutical agent conjugates |
US6329508B1 (en) | 1989-09-07 | 2001-12-11 | Alkermes, Inc. | Transferrin receptor reactive chimeric antibodies |
US5182107A (en) | 1989-09-07 | 1993-01-26 | Alkermes, Inc. | Transferrin receptor specific antibody-neuropharmaceutical or diagnostic agent conjugates |
US5672683A (en) | 1989-09-07 | 1997-09-30 | Alkermes, Inc. | Transferrin neuropharmaceutical agent fusion protein |
US5208020A (en) | 1989-10-25 | 1993-05-04 | Immunogen Inc. | Cytotoxic agents comprising maytansinoids and their therapeutic use |
EP0525005B1 (en) | 1990-03-27 | 1997-06-11 | The Salk Institute For Biological Studies | Method for inhibiting cell growth and compositions useful therefor |
US5229275A (en) | 1990-04-26 | 1993-07-20 | Akzo N.V. | In-vitro method for producing antigen-specific human monoclonal antibodies |
ATE439859T1 (de) | 1990-08-23 | 2009-09-15 | Univ North Carolina | Transferrin bindende proteine aus neisseria- gonorrhoeae und neisseria-meningitidis. ihre verwendung in einem impfstoff |
US5912336A (en) | 1990-08-23 | 1999-06-15 | University Of North Carolina At Chapel Hill | Isolated nucleic acid molecules encoding transferrin binding proteins from Neisseria gonorrhoeae and Neisseria meningitidis |
JPH04187096A (ja) | 1990-11-20 | 1992-07-03 | Takeda Chem Ind Ltd | 二重特異性を有するハイブリッド・モノクローナル抗体 |
US6099842A (en) | 1990-12-03 | 2000-08-08 | The United States Of America As Represented By The Department Of Health And Human Services | Recombinant immunotoxin composed of a single chain antibody reacting with the human transferrin receptor and diptheria toxin |
DE4110409C2 (de) | 1991-03-29 | 1999-05-27 | Boehringer Ingelheim Int | Neue Protein-Polykation-Konjugate |
US6287792B1 (en) | 1991-06-17 | 2001-09-11 | The Regents Of The University Of California | Drug delivery of antisense oligonucleotides and peptides to tissues in vivo and to cells using avidin-biotin technology |
US5637481A (en) | 1993-02-01 | 1997-06-10 | Bristol-Myers Squibb Company | Expression vectors encoding bispecific fusion proteins and methods of producing biologically active bispecific fusion proteins in a mammalian cell |
EP1266965B1 (en) | 1991-07-25 | 2006-05-24 | Biogen Idec Inc. | Recombinant antibodies for human therapy |
MX9204374A (es) | 1991-07-25 | 1993-03-01 | Idec Pharma Corp | Anticuerpo recombinante y metodo para su produccion. |
US5565332A (en) | 1991-09-23 | 1996-10-15 | Medical Research Council | Production of chimeric antibodies - a combinatorial approach |
US5254342A (en) | 1991-09-30 | 1993-10-19 | University Of Southern California | Compositions and methods for enhanced transepithelial and transendothelial transport or active agents |
WO1993008829A1 (en) | 1991-11-04 | 1993-05-13 | The Regents Of The University Of California | Compositions that mediate killing of hiv-infected cells |
EP0614375A1 (en) | 1991-11-26 | 1994-09-14 | Alkermes, Inc. | Process for the preparation of transferrin receptor specific antibody-neuropharmaceutical or diagnostic agent conjugates |
CA2128862C (en) | 1992-02-11 | 2008-05-20 | Jonathan G. Seidman | Homogenotization of gene-targeting events |
US5573905A (en) | 1992-03-30 | 1996-11-12 | The Scripps Research Institute | Encoded combinatorial chemical libraries |
US5648469A (en) | 1992-04-20 | 1997-07-15 | The Salk Institute For Biological Studies | Monoclonal antibodies reactive with transferrin receptor cytoplasmic domain |
FR2692592B1 (fr) | 1992-06-19 | 1995-03-31 | Pasteur Merieux Serums Vacc | Fragments d'ADN codant pour les sous-unités du récepteur de la transferrine de Neisseria meningitidis et procédés les exprimant. |
ATE191853T1 (de) | 1992-07-27 | 2000-05-15 | Us Health | Zielgerichte liposome zur blut-hirne schranke |
US6361779B1 (en) | 1993-11-08 | 2002-03-26 | Aventis Pasteur Limited | Transferrin receptor genes |
JPH09506247A (ja) | 1993-11-08 | 1997-06-24 | コノート ラボラトリーズ リミテッド | ヘモフィリス属菌株トランスフェリン受容体遺伝子 |
WO1995015982A2 (en) | 1993-12-08 | 1995-06-15 | Genzyme Corporation | Process for generating specific antibodies |
IL112372A (en) | 1994-02-07 | 2001-08-26 | Res Dev Foundation | Non-viral vector for the delivery of genetic information to cells |
US5731168A (en) | 1995-03-01 | 1998-03-24 | Genentech, Inc. | Method for making heteromultimeric polypeptides |
US6015555A (en) | 1995-05-19 | 2000-01-18 | Alkermes, Inc. | Transferrin receptor specific antibody-neuropharmaceutical or diagnostic agent conjugates |
US5817789A (en) | 1995-06-06 | 1998-10-06 | Transkaryotic Therapies, Inc. | Chimeric proteins for use in transport of a selected substance into cells |
JP3973169B2 (ja) | 1995-09-26 | 2007-09-12 | 栄研化学株式会社 | トランスフェリン−トランスフェリンレセプター・コンプレックス測定試薬および測定方法 |
US6290970B1 (en) | 1995-10-11 | 2001-09-18 | Aventis Pasteur Limited | Transferrin receptor protein of Moraxella |
US6497881B1 (en) | 1995-11-30 | 2002-12-24 | New York University | High efficiency tissue specific compound delivery system using streptavidin-protein a fusion protein |
WO1997028817A1 (en) | 1996-02-09 | 1997-08-14 | Cheng Pi Wan | Receptor ligand-facilitated delivery of biologically active molecules |
GB9603256D0 (en) | 1996-02-16 | 1996-04-17 | Wellcome Found | Antibodies |
US6440701B1 (en) | 1996-03-08 | 2002-08-27 | Aventis Pasteur Limited | Transferrin receptor genes of Moraxella |
US6090576A (en) | 1996-03-08 | 2000-07-18 | Connaught Laboratories Limited | DNA encoding a transferrin receptor of Moraxella |
WO1998022092A1 (en) | 1996-11-22 | 1998-05-28 | The Regents Of The University Of California | Transport of liposomes across the blood-brain barrier |
JPH10245400A (ja) | 1997-02-28 | 1998-09-14 | Eiken Chem Co Ltd | トランスフェリンレセプターの安定化方法 |
EP0994903B1 (en) | 1997-06-24 | 2005-05-25 | Genentech, Inc. | Methods and compositions for galactosylated glycoproteins |
WO1999022764A1 (en) | 1997-10-31 | 1999-05-14 | Genentech, Inc. | Methods and compositions comprising glycoprotein glycoforms |
WO1999042127A2 (en) | 1998-02-24 | 1999-08-26 | Receptron, Inc. | Receptor derived peptides as modulators of receptor activity |
PT1068241E (pt) | 1998-04-02 | 2007-11-19 | Genentech Inc | Variantes de anticorpos e respectivos fragmentos |
DK1071700T3 (da) | 1998-04-20 | 2010-06-07 | Glycart Biotechnology Ag | Glykosylerings-modifikation af antistoffer til forbedring af antistofafhængig cellulær cytotoksicitet |
US6891028B1 (en) | 1998-11-06 | 2005-05-10 | Cedars-Sinai Medical Center | Nucleic acids encoding transferrin receptor-like proteins |
CA2350415A1 (en) | 1998-11-18 | 2000-05-25 | Incyte Pharmaceuticals, Inc. | Inflammation-associated genes |
ATE483816T1 (de) | 1998-11-19 | 2010-10-15 | Univ Georgetown | Systemisches virus/ligand genabgabemittel und gentherapie |
EP2364997A3 (en) | 1999-01-15 | 2012-07-04 | Genentech, Inc. | Polypeptide variants with altered effector function |
US7780882B2 (en) | 1999-02-22 | 2010-08-24 | Georgetown University | Simplified and improved method for preparing an antibody or an antibody fragment targeted immunoliposome for systemic administration of a therapeutic or diagnostic agent |
CA2362550C (en) | 1999-02-22 | 2010-05-11 | Georgetown University | Antibody fragment-targeted immunoliposomes for systemic gene delivery |
GB9908195D0 (en) | 1999-04-09 | 1999-06-02 | Microbiological Res Authority | Treatment of intracellular infection |
US7241449B1 (en) | 1999-04-12 | 2007-07-10 | Aventis Pasteur Limited | Transferrin receptor genes of moraxella |
US6511967B1 (en) | 1999-04-23 | 2003-01-28 | The General Hospital Corporation | Use of an internalizing transferrin receptor to image transgene expression |
EP1409654B1 (en) | 1999-06-16 | 2008-08-20 | Boston Biomedical Research Institute | Immunological control of beta-amyloid levels in vivo |
US20040146516A1 (en) | 1999-06-17 | 2004-07-29 | Utah Ventures Ii L.P. | Lumen-exposed molecules and methods for targeted delivery |
AU6607100A (en) | 1999-07-23 | 2001-02-13 | Regents Of The University Of California, The | Anti-growth factor receptor avidin fusion proteins as universal vectors for drugdelivery |
JP2003516745A (ja) | 1999-12-13 | 2003-05-20 | ケンブリッジ アンティボディー テクノロジー リミティド | 脳特定結合性メンバー |
AU2001244602A1 (en) | 2000-03-30 | 2001-10-15 | Ajinomoto Co. Inc. | Drugs retained in target tissue over long time |
LT2857516T (lt) | 2000-04-11 | 2017-09-11 | Genentech, Inc. | Multivalentiniai antikūnai ir jų panaudojimas |
WO2001082972A2 (en) | 2000-04-23 | 2001-11-08 | Arizeke Pharmaceuticals, Inc. | Compositions comprising carriers and transportable complexes |
US6372250B1 (en) | 2000-04-25 | 2002-04-16 | The Regents Of The University Of California | Non-invasive gene targeting to the brain |
GB0027328D0 (en) | 2000-06-23 | 2000-12-27 | Aventis Pharma Inc | Bioengineered vehicles for targeted nucleic acid delivery |
US20020048550A1 (en) | 2000-07-20 | 2002-04-25 | Vallera Daniel A. | Radiolabeled immunotoxins |
ATE441663T1 (de) | 2000-09-06 | 2009-09-15 | Aventis Pharma Sa | Verfahren und zusammensetzungen für amyloidosis- verbundene krankheiten |
JP2002095476A (ja) | 2000-09-20 | 2002-04-02 | Eisai Co Ltd | トランスフェリン受容体を介した遺伝子導入法 |
AU2002236499A8 (en) | 2000-11-30 | 2009-12-03 | Uab Research Foundation | Receptor-mediated uptake of peptides that bind the human transferrin receptor |
US20030165853A1 (en) | 2000-12-04 | 2003-09-04 | The Regents Of The University Of California Office Of Technology Transfer | Antisense imaging of gene expression of the brain in vivo |
US20030133939A1 (en) | 2001-01-17 | 2003-07-17 | Genecraft, Inc. | Binding domain-immunoglobulin fusion proteins |
US7829084B2 (en) | 2001-01-17 | 2010-11-09 | Trubion Pharmaceuticals, Inc. | Binding constructs and methods for use thereof |
US7754208B2 (en) | 2001-01-17 | 2010-07-13 | Trubion Pharmaceuticals, Inc. | Binding domain-immunoglobulin fusion proteins |
DE10121982B4 (de) | 2001-05-05 | 2008-01-24 | Lts Lohmann Therapie-Systeme Ag | Nanopartikel aus Protein mit gekoppeltem Apolipoprotein E zur Überwindung der Blut-Hirn-Schranke und Verfahren zu ihrer Herstellung |
WO2002094191A2 (en) | 2001-05-23 | 2002-11-28 | New York University | Detection of alzheimer's amyloid by magnetic resonance imaging |
US20100081792A1 (en) | 2001-06-28 | 2010-04-01 | Smithkline Beecham Corporation | Ligand |
NZ592087A (en) | 2001-08-03 | 2012-11-30 | Roche Glycart Ag | Antibody glycosylation variants having increased antibody-dependent cellular cytotoxicity |
US7176278B2 (en) | 2001-08-30 | 2007-02-13 | Biorexis Technology, Inc. | Modified transferrin fusion proteins |
WO2004019872A2 (en) | 2002-08-30 | 2004-03-11 | Biorexis Pharmaceutical Corporation | Oral delivery of modified transferrin fusion proteins |
US20030226155A1 (en) | 2001-08-30 | 2003-12-04 | Biorexis Pharmaceutical Corporation | Modified transferrin-antibody fusion proteins |
US20040023334A1 (en) | 2001-08-30 | 2004-02-05 | Biorexis Pharmaceutical Corporation | Modified transferrin fusion proteins |
JP2005532253A (ja) | 2001-10-25 | 2005-10-27 | ジェネンテック・インコーポレーテッド | 糖タンパク質組成物 |
US20040093621A1 (en) | 2001-12-25 | 2004-05-13 | Kyowa Hakko Kogyo Co., Ltd | Antibody composition which specifically binds to CD20 |
US7998704B2 (en) | 2002-03-07 | 2011-08-16 | Carnegie Mellon University | Methods for magnetic resonance imaging |
JP2005518816A (ja) | 2002-03-07 | 2005-06-30 | カーネギー メロン ユニバーシティ | 磁気共鳴イメージング用コントラスト剤及びそれに関する方法 |
US20050249721A1 (en) | 2002-04-02 | 2005-11-10 | Houston L L | Compositions and methods for targeted biological delivery of molecular carriers |
CN1713920A (zh) | 2002-08-30 | 2005-12-28 | 比奥雷克西斯药物公司 | 被修饰的转铁蛋白融合蛋白 |
DE60330680D1 (de) | 2002-08-30 | 2010-02-04 | Biorexis Pharmaceutical Corp | Transferrin-fusionsproteinbibliotheken |
EP1558650A2 (en) | 2002-11-08 | 2005-08-03 | Ablynx N.V. | Camelidae antibodies against immunoglobulin e and use thereof for the treatment of allergic disorders |
US20040102369A1 (en) | 2002-11-27 | 2004-05-27 | The Regents Of The University Of California | Transport of basic fibroblast growth factor across the blood brain barrier |
US20050142141A1 (en) | 2002-11-27 | 2005-06-30 | Pardridge William M. | Delivery of enzymes to the brain |
WO2004050062A2 (en) | 2002-12-03 | 2004-06-17 | Blanchette Rockefeller Neurosciences Institute | Artificial low-density lipoprotein carriers for transport of substances across the blood-brain barrier |
EP1587524A4 (en) | 2003-01-09 | 2006-07-26 | Arizeke Pharmaceuticals Inc | COMPOSITIONS AND METHODS FOR TARGET BIOLOGICAL TRANSPORT OF MOLECULAR MEDIA |
JP4187096B2 (ja) | 2003-01-15 | 2008-11-26 | 独立行政法人科学技術振興機構 | 3次元フォトニック結晶製造方法 |
MXPA05008487A (es) * | 2003-02-10 | 2006-03-10 | To Bbb Holding B V | Acidos nucleicos expresados en forma diferencial en la barrera hemato-encefalica bajo condiciones de inflamacion. |
CN1788017B (zh) * | 2003-02-10 | 2013-04-24 | to-BBB控股股份有限公司 | 炎症状态下在血脑屏障中差异表达的核酸 |
WO2004078777A2 (en) | 2003-03-04 | 2004-09-16 | Biorexis Pharmaceutical Corporation | Dipeptidyl-peptidase protected proteins |
AU2003286870A1 (en) | 2003-06-05 | 2005-01-04 | Salk Institute For Biological Studies | Targeting polypeptides to the central nervous system |
JP2007508806A (ja) | 2003-08-04 | 2007-04-12 | アプライド リサーチ システムズ エーアールエス ホールディング ナームロゼ フェンノートシャップ | 新規治療融合タンパク質 |
US20050042298A1 (en) | 2003-08-20 | 2005-02-24 | Pardridge William M. | Immunonanoparticles |
EP1663278A4 (en) | 2003-08-28 | 2009-07-29 | Biorexis Pharmaceutical Corp | EPO MIMETIC PEPTIDES AND FUSION PROTEINS |
WO2005025511A2 (en) | 2003-09-10 | 2005-03-24 | Cedars-Sinai Medical Center | Potassium channel mediated delivery of agents through the blood-brain barrier |
WO2005044859A2 (en) | 2003-11-05 | 2005-05-19 | Glycart Biotechnology Ag | Cd20 antibodies with increased fc receptor binding affinity and effector function |
US20050202075A1 (en) | 2004-03-12 | 2005-09-15 | Pardridge William M. | Delivery of genes encoding short hairpin RNA using receptor-specific nanocontainers |
US20060029597A1 (en) | 2004-03-31 | 2006-02-09 | Chimeric Technologies | IgA antibody protein as a cytotoxic drug |
AU2005233254B2 (en) | 2004-03-31 | 2011-11-24 | Kellbenx, Inc. | Monoclonal antibodies with specificity for fetal erythroid cells |
ATE537189T1 (de) | 2004-04-30 | 2011-12-15 | Inst Nat Sante Rech Med | Anti-tfr-antikörper |
AU2005249553B2 (en) | 2004-06-02 | 2010-02-11 | Jan E. Schnitzer | Imaging and therapeutic agents targeting proteins expressed on endothelial cell surface |
US7572895B2 (en) | 2004-06-07 | 2009-08-11 | Raven Biotechnologies, Inc. | Transferrin receptor antibodies |
US20060018897A1 (en) | 2004-06-28 | 2006-01-26 | Transtarget Inc. | Bispecific antibodies |
CA2614068A1 (en) | 2004-06-29 | 2006-08-24 | Massachusetts Institute Of Technology | Methods and compositions related to the modulation of intercellular junctions |
CA2583202A1 (en) | 2004-10-04 | 2006-04-27 | Trinity Biosystems, Inc. | Methods and compositions for needleless delivery of macromolecules |
EP1858546A4 (en) | 2005-03-04 | 2009-03-04 | Biorexis Pharmaceutical Corp | MODIFIED TRANSFERRINFUSION PROTEINS |
EP1888034A2 (en) | 2005-05-26 | 2008-02-20 | Yissum Research Development Company, of The Hebrew University of Jerusalem | Compositions and methods using same for delivering agents into a target organ protected by a blood barrier |
JP2005321411A (ja) | 2005-06-10 | 2005-11-17 | Eiken Chem Co Ltd | トランスフェリン−トランスフェリンレセプター・コンプレックス測定試薬および測定方法 |
US7736647B2 (en) | 2005-06-15 | 2010-06-15 | Monoclonal Antibodies Therapeutics | Anti-CD71 monoclonal antibodies and uses thereof for treating malignant tumor cells |
CA2611054C (en) | 2005-06-17 | 2017-05-09 | National Research Council Of Canada | Novel a.beta.-binding polypeptides and derivatives and uses thereof |
AU2006283726C1 (en) | 2005-08-24 | 2015-05-07 | Immunogen, Inc. | Process for preparing maytansinoid antibody conjugates |
WO2007027559A2 (en) | 2005-08-29 | 2007-03-08 | Shashoua Victor E | Neuroprotective and neurorestorative methods and compositions |
US8142781B2 (en) | 2005-10-07 | 2012-03-27 | Armagen Technologies, Inc. | Fusion proteins for blood-brain barrier delivery |
US8124095B2 (en) | 2005-10-07 | 2012-02-28 | Armagen Technologies, Inc. | Fusion proteins for delivery of erythropoietin to the CNS |
JP2009511060A (ja) | 2005-10-14 | 2009-03-19 | バイオレクシス ファーマシューティカル コーポレーション | ナトリウム利尿ペプチド修飾されたトランスフェリン融合タンパク質 |
WO2007067597A2 (en) | 2005-12-05 | 2007-06-14 | Trinity Biosystems, Inc. | Methods and compositions for needleless delivery of binding partners |
US20090304684A1 (en) | 2005-12-05 | 2009-12-10 | Trinity Biosystems, Inc. | Methods and compositions for needleless delivery of antibodies |
CA2632822C (en) | 2005-12-12 | 2018-08-28 | Ruth Greferath | A beta 1-42 specific monoclonal antibodies with therapeutic properties |
WO2007103288A2 (en) | 2006-03-02 | 2007-09-13 | Seattle Genetics, Inc. | Engineered antibody drug conjugates |
WO2007112451A2 (en) | 2006-03-28 | 2007-10-04 | University Of Washington | Covalent conjugates between endoperoxides and transferrin and lactoferrin receptor-binding agents |
NZ571038A (en) * | 2006-03-30 | 2011-03-31 | Glaxo Group Ltd | Antibodies against amyloid-beta peptide |
WO2008054544A2 (en) | 2006-05-22 | 2008-05-08 | Immune Disease Institute, Inc. | Method for delivery across the blood brain barrier |
WO2007143711A2 (en) * | 2006-06-07 | 2007-12-13 | Wisconsin Alumni Research Foundation | Blood-brain barrier targeting antibodies |
WO2008011348A2 (en) | 2006-07-14 | 2008-01-24 | Ac Immune S.A. | Humanized antibody against amyloid beta |
JP2009544406A (ja) | 2006-07-27 | 2009-12-17 | ユニヴァースティ オブ ヴァージニア パテント ファウンデイション | 治療又は診断用薬の頭蓋内注入用システム及び方法 |
US20090092660A1 (en) | 2006-08-09 | 2009-04-09 | Trinity Biosystems, Inc. | Methods and compositions for needleless delivery of particles |
WO2008021412A2 (en) | 2006-08-14 | 2008-02-21 | Biorexis Pharmaceutical Corporation | Interferon beta and transferrin fusion proteins |
JP5959795B2 (ja) * | 2006-08-18 | 2016-08-02 | アーメイゲン・テクノロジーズ・インコーポレイテッドArmagen Technologies, Inc. | 血液脳関門送達のための物質 |
EP2059533B1 (en) | 2006-08-30 | 2012-11-14 | Genentech, Inc. | Multispecific antibodies |
US8821943B2 (en) | 2006-09-12 | 2014-09-02 | Board Of Regents Of The University Of Nebraska | Methods and compositions for targeted delivery of therapeutic agents |
WO2008033395A2 (en) | 2006-09-14 | 2008-03-20 | Biorexis Pharmaceutical Corporation | Melanocortin and transferrin fusion proteins |
EP2089419A2 (en) | 2006-10-27 | 2009-08-19 | Zapaloid Limited | Inhibition of beta-amyloid aggregation |
CN101245107B (zh) * | 2007-02-14 | 2010-10-13 | 中国人民解放军军事医学科学院生物工程研究所 | 抗人转铁蛋白受体人源抗体及其应用 |
EP2124916A1 (en) | 2007-02-27 | 2009-12-02 | Government of the United States of America, as represented by the Secretary, Department of Health and Human Services | Use of histone deacetylase inhibitors for the treatment of central nervous system metastases |
ES2426684T3 (es) | 2007-03-23 | 2013-10-24 | To-Bbb Holding B.V. | Conjugados para el suministro dirigido de fármacos a través de la barrera hematoencefálica |
EP1975178A1 (en) | 2007-03-30 | 2008-10-01 | f-star Biotechnologische Forschungs- und Entwicklungsges.m.b.H. | Transcytotic modular antibody |
EP3351270A1 (en) | 2007-05-23 | 2018-07-25 | The Trustees of the University of Pennsylvania | Targeted carriers for intracellular drug delivery |
KR101600095B1 (ko) | 2007-06-12 | 2016-03-07 | 에이씨 이뮨 에스.에이. | 모노클로널 항 베타 아밀로이드 항체 |
CN101820911B (zh) | 2007-06-12 | 2015-05-06 | Ac免疫有限公司 | β淀粉样蛋白的人源化抗体 |
GB0711424D0 (en) | 2007-06-13 | 2007-07-25 | Novozymes Delta Ltd | Recombinant transferrin mutants |
US7973019B1 (en) | 2007-10-03 | 2011-07-05 | Alcon Research, Ltd. | Transferrin/transferrin receptor-mediated siRNA delivery |
GB0725065D0 (en) | 2007-12-21 | 2008-01-30 | Got A Gene Ab | Method |
CA2709847C (en) | 2008-01-07 | 2018-07-10 | Amgen Inc. | Method for making antibody fc-heterodimeric molecules using electrostatic steering effects |
WO2009094561A1 (en) | 2008-01-24 | 2009-07-30 | The Government Of The United States Of America As Represented By The Secretary Of The Departmentof | Induced internalization of surface receptors |
JP2011517561A (ja) | 2008-03-31 | 2011-06-16 | グラクソ グループ リミテッド | 薬物融合体および複合体 |
US20110250199A1 (en) | 2008-06-04 | 2011-10-13 | The Government of the United States of America as represented by the Secretary of the Department.... | Immunotoxins and uses thereof |
EP2303926A1 (en) * | 2008-06-20 | 2011-04-06 | Oklahoma Medical Research Foundation | Immunogenic memapsin 2 -secretase peptides and methods of use |
US20100077498A1 (en) | 2008-09-11 | 2010-03-25 | Pardridge William M | Compositions and methods for blood-brain barrier delivery in the mouse |
US8946165B2 (en) | 2008-09-29 | 2015-02-03 | The Regents Of The University Of California | Compounds for reversing and inhibiting protein aggregation, and methods for making and using them |
US20100098693A1 (en) | 2008-10-07 | 2010-04-22 | Pardridge William M | Compositions and methods for blood-brain barrier delivery of organophosphatases |
BRPI1006141B8 (pt) | 2009-01-12 | 2021-05-25 | Cytomx Therapeutics Llc | composições de anticorpo modificado, métodos para preparar e usar as mesmas |
US8530629B2 (en) * | 2009-01-30 | 2013-09-10 | Ab Biosciences, Inc. | Lowered affinity antibodies and uses therefor |
CA2748889A1 (en) | 2009-03-18 | 2010-09-23 | Armagen Technologies, Inc. | Compositions and methods for blood-brain barrier delivery of igg-decoy receptor fusion proteins |
WO2010120262A1 (en) | 2009-04-14 | 2010-10-21 | Smith Holdings, Llc | Methods and compositions for the treatment of medical conditions involving cellular programming |
DK2443149T3 (en) * | 2009-06-15 | 2016-12-12 | Vib Vzw | BACE1 inhibitory ANTIBODIES |
WO2011009624A1 (en) | 2009-07-22 | 2011-01-27 | Cenix Bioscience Gmbh | Delivery system and conjugates for compound delivery via naturally occurring intracellular transport routes |
UY32808A (es) * | 2009-07-29 | 2011-02-28 | Abbott Lab | Inmunoglobulinas como dominio variable dual y usos de las mismas |
US9149544B2 (en) | 2009-11-06 | 2015-10-06 | The Penn State Research Foundation | Bioconjugation of calcium phosphosilicate nanoparticles for selective targeting of cells in vivo |
FR2953841B1 (fr) | 2009-12-16 | 2011-12-30 | Centre Nat Rech Scient | Anticorps diriges contre le recepteur de la transferrine et leurs utilisations pour l'immunotherapie des tumeurs qui dependent du fer |
JP5856073B2 (ja) | 2009-12-29 | 2016-02-09 | エマージェント プロダクト デベロップメント シアトル, エルエルシー | Ron結合構築体およびその使用方法 |
US8734799B2 (en) | 2010-04-13 | 2014-05-27 | The Regents Of The University Of California | Unconjugated anti-TfR antibodies and compositions thereof for the treatment of cancer |
FR2959416B1 (fr) | 2010-05-03 | 2012-06-22 | Monoclonal Antibodies Therapeutics Mat Biopharma | Utilisation d'anticorps anti-cd71 pour la preparation d'un medicament |
CN103443125B (zh) | 2010-11-30 | 2019-05-03 | 霍夫曼-拉罗奇有限公司 | 低亲和力血脑屏障受体抗体及其用途 |
JP6210017B2 (ja) | 2014-04-17 | 2017-10-11 | マツダ株式会社 | 自動変速機 |
-
2011
- 2011-11-29 CN CN201180057610.XA patent/CN103443125B/zh active Active
- 2011-11-29 AU AU2011336716A patent/AU2011336716B2/en active Active
- 2011-11-29 RS RS20170442A patent/RS55920B1/sr unknown
- 2011-11-29 AR ARP110104424A patent/AR084020A1/es unknown
- 2011-11-29 EA EA201390785A patent/EA034333B1/ru not_active IP Right Cessation
- 2011-11-29 EP EP11794336.5A patent/EP2646470B1/en not_active Revoked
- 2011-11-29 UA UAA201308125A patent/UA117801C2/uk unknown
- 2011-11-29 TW TW100143781A patent/TW201305200A/zh unknown
- 2011-11-29 KR KR1020197035389A patent/KR102099462B1/ko active IP Right Grant
- 2011-11-29 ES ES11794336T patent/ES2631356T3/es active Active
- 2011-11-29 EP EP16193195.1A patent/EP3208282A1/en not_active Ceased
- 2011-11-29 WO PCT/US2011/062445 patent/WO2012075037A1/en active Application Filing
- 2011-11-29 US US13/306,524 patent/US20120171120A1/en not_active Abandoned
- 2011-11-29 NZ NZ706751A patent/NZ706751A/en unknown
- 2011-11-29 KR KR1020137016918A patent/KR102052571B1/ko active IP Right Grant
- 2011-11-29 PE PE2013001326A patent/PE20140981A1/es not_active Application Discontinuation
- 2011-11-29 CA CA2818173A patent/CA2818173C/en active Active
- 2011-11-29 KR KR1020207009790A patent/KR102188544B1/ko active IP Right Grant
- 2011-11-29 LT LTEP11794336.5T patent/LT2646470T/lt unknown
- 2011-11-29 PL PL11794336T patent/PL2646470T3/pl unknown
- 2011-11-29 CN CN201910387173.6A patent/CN110251668A/zh active Pending
- 2011-11-29 SG SG2013040845A patent/SG190900A1/en unknown
- 2011-11-29 SI SI201131173A patent/SI2646470T1/sl unknown
- 2011-11-29 PT PT117943365T patent/PT2646470T/pt unknown
- 2011-11-29 TW TW106112654A patent/TWI689314B/zh active
- 2011-11-29 MY MYPI2013001958A patent/MY188469A/en unknown
- 2011-11-29 BR BR112013013083A patent/BR112013013083A2/pt not_active Application Discontinuation
- 2011-11-29 JP JP2013542109A patent/JP6125430B2/ja active Active
- 2011-11-29 DK DK11794336.5T patent/DK2646470T3/en active
- 2011-11-29 MX MX2013005793A patent/MX358367B/es active IP Right Grant
- 2011-11-29 TW TW109106547A patent/TW202021621A/zh unknown
- 2011-11-29 NZ NZ724348A patent/NZ724348A/en unknown
-
2013
- 2013-05-16 ZA ZA2013/03572A patent/ZA201303572B/en unknown
- 2013-05-30 CL CL2013001535A patent/CL2013001535A1/es unknown
- 2013-05-31 CR CR20130255A patent/CR20130255A/es unknown
- 2013-06-19 MA MA36025A patent/MA34749B1/fr unknown
- 2013-06-28 EC ECSP13012724 patent/ECSP13012724A/es unknown
- 2013-06-28 CO CO13154248A patent/CO6721052A2/es unknown
-
2014
- 2014-12-19 US US14/577,006 patent/US9611323B2/en active Active
-
2016
- 2016-04-18 AU AU2016202447A patent/AU2016202447B2/en active Active
-
2017
- 2017-01-06 JP JP2017001025A patent/JP6490721B2/ja active Active
- 2017-02-17 US US15/435,658 patent/US20170260292A1/en not_active Abandoned
- 2017-04-12 HR HRP20170590TT patent/HRP20170590T1/hr unknown
- 2017-04-28 CY CY20171100475T patent/CY1118906T1/el unknown
-
2018
- 2018-09-14 US US16/131,591 patent/US10941215B2/en active Active
-
2019
- 2019-02-26 JP JP2019032385A patent/JP6800260B2/ja active Active
-
2021
- 2021-01-28 US US17/161,068 patent/US20210292440A1/en active Pending
- 2021-05-03 IL IL282877A patent/IL282877A/en unknown
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
UA117801C2 (uk) | Лікування неврологічного порушення за допомогою антитіла, яке має низьку афінність до рецептора гематоенцефалічного бар'єру | |
AU2016202447A1 (en) | Low affinity blood brain barrier receptor antibodies and uses therefor | |
PH12015502565A1 (en) | Anti-transferrin receptor antibodies and methods of use | |
TN2012000462A1 (en) | Anti-cd40 antibodies | |
PH12015501059A1 (en) | Anti-hemagglutinin antibodies and methods of use | |
PH12014501427B1 (en) | Anti-phf-tau antibodies and their uses | |
PH12017500864A1 (en) | Anti-notch1 antibodies | |
PH12014501108A1 (en) | Anti-il-36r antibodies | |
EA201590993A1 (ru) | Гетеродимерные иммуноглобулины | |
NZ604510A (en) | Dilutable biocidal compositions and methods of use | |
MX346500B (es) | Metodos y composiciones para inmunoterapia para enfermedad neural. | |
PH12014502406A1 (en) | Anti-il-23p19 antibodies | |
MX343659B (es) | Proteínas de unión receptoras fc. | |
EA201491357A1 (ru) | Анти-lrp5 антитела и способы их применения | |
PH12015500752A1 (en) | Her3 antigen binding proteins binding to the beta-hairpin of her3 | |
MX336323B (es) | Anticuerpos de anti-poliubiquitina y metodos de uso. | |
MX2013002960A (es) | Composiciones de anticuerpo y metodos de uso. | |
IN2014DN09717A (uk) | ||
MX2010000979A (es) | Metodos y composiciones para tratar enfermedad autoinmune. | |
MX2015004892A (es) | Metodos y composiciones que se relacionan con anticuerpos de receptor anti-il-21. | |
TN2014000207A1 (en) | Anti il-36r antibodies |